| 1 |
NCT03233841 |
Recruiting |
Farber Disease Natural History Study |
- Farber Disease
- Farber's Disease
- Farber Lipogranulomatosis
- (and 4 more...)
|
|
Observational
|
|
- Enzyvant Farber GmbH
- Enzyvant Farber GmbH
|
Industry |
- Observational Model: Cohort
- Time Perspective: Other
|
- Establish a dataset on the natural history of Farber Disease
|
40 |
All |
Child, Adult, Older Adult |
NCT03233841 |
RVT-801-0001 |
|
November 22, 2017 |
November 2019 |
November 2019 |
July 31, 2017 |
May 3, 2018 |
|
- UCSF Benioff Children's Hospital Oakland
Oakland, California, United States - Children's National Health System
Washington, District of Columbia, United States - Hospital de Niños de la Santisima Trinidad
Córdoba, CP, Argentina - (and 6 more...)
|
|
| 2 |
NCT02298634 |
Recruiting |
Biomarker for Farber Disease |
- Farber's Lipogranulomatosis
- Ceramidase Deficiency
- Farber Disease
- (and 2 more...)
|
|
Observational
|
|
- University of Rostock
- Centogene AG Rostock
|
Other / Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Development of a new MS-based biomarker for the early and sensitive diagnosis of Farber disease using the technique of Mass-spectometry 10ml EDTA blood, saliva tube and a dry blood spot filter card
- Testing for clinical robustness, specificity and long-term stability of the biomarker
|
50 |
All |
2 Months and older (Child, Adult, Older Adult) |
NCT02298634 |
BFD 07-2014 |
BioFarber |
November 2014 |
November 2019 |
November 2019 |
November 24, 2014 |
December 11, 2017 |
|
- Albrecht-Kossel-Institute for Neuroregeneration (AKos) Centre for Mental Health Disease University of Rostock
Rostock, Germany
|
|
| 3 |
NCT00165269 |
Completed |
Mantle Irradiation for Hodgkin's Disease |
|
- Procedure: Mantle irradiation
|
Interventional
|
Phase 2 |
- Dana-Farber Cancer Institute
- Brigham and Women's Hospital
- Massachusetts General Hospital
- Dana-Farber Cancer Institute
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To evaluate the risks and benefits of mantle field irradiation alone in treating Hodgkin disease patients.
|
100 |
All |
18 Years and older (Adult, Older Adult) |
NCT00165269 |
92-035 |
|
May 1992 |
June 2000 |
February 2008 |
September 14, 2005 |
November 2, 2009 |
|
- Dana-Farber Cancer Center
Boston, Massachusetts, United States - Massachusetts General Hospital
Boston, Massachusetts, United States
|
|
| 4 |
NCT02340676 |
Active, not recruiting |
A Phase II Trial of Low-Dose Interleukin-2 (IL-2) Added to Extra-Corporeal Photopheresis for Steroid-Refractory Chronic Graft-versus-Host-Disease |
- Chronic Graft-versus-host-disease
|
- Procedure: Extracorporeal Photopheresis (ECP)
- Drug: Interleukin-2
|
Interventional
|
Phase 2 |
- Dana-Farber Cancer Institute
- Prometheus Laboratories
- Dana-Farber Cancer Institute
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in Clinical cGVHD Invovlement from Baseline to Week 8 and Week 16
- Number of Grade 3 or higher Toxicities related to ECP plus low-dose SC IL-2 therapy
- Change in Regulatory T cell counts during ECP plus low-dose daily SC IL-2
- (and 5 more...)
|
25 |
All |
18 Years and older (Adult, Older Adult) |
NCT02340676 |
14-479 |
|
February 2015 |
August 2017 |
March 2019 |
January 19, 2015 |
May 1, 2018 |
|
- Dana-Farber Cancer Insitute
Boston, Massachusetts, United States
|
|
| 5 |
NCT02176031 |
Recruiting |
Phase II Trial of Natalizumab (Tysabri®) Plus Prednisone for Initial Therapy of Acute Graft Versus Host Disease (aGVHD) of the Gastrointestinal Tract |
- Graft Versus Host Disease
|
- Drug: Natalizumab
- Drug: Methylprednisolone
|
Interventional
|
Phase 2 |
- Dana-Farber Cancer Institute
- Biogen
- Dana-Farber Cancer Institute
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- GVHD-free survival rate
- GVHD Response Rate
- GI aGVHD Response Rate
- (and 4 more...)
|
30 |
All |
18 Years and older (Adult, Older Adult) |
NCT02176031 |
14-140 |
|
January 2015 |
April 2019 |
March 2020 |
June 26, 2014 |
May 1, 2018 |
|
- Massachusetts General Hospital
Boston, Massachusetts, United States - Dana-Farber Cancer Institute
Boston, Massachusetts, United States
|
|
| 6 |
NCT02318082 |
Active, not recruiting |
Study of Individual Adult and Pediatric Patient Dose-escalated Interleukin-2 Therapy for Refractory Chronic Graft-versus-Host-Disease |
- Chronic Versus Graft Host Disease
|
|
Interventional
|
Phase 1 |
- Dana-Farber Cancer Institute
- Dana-Farber Cancer Institute
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum Tolerated Dose (MTD) of 8-week Individual patient dose-escalated Interleukin-2
- Overall cGVHD Clinical Response Rate
- Overall Survival Rate
- Malignant Relapse Rate
|
21 |
All |
2 Years and older (Child, Adult, Older Adult) |
NCT02318082 |
14-452 |
|
February 2015 |
October 2017 |
December 2020 |
December 17, 2014 |
January 26, 2018 |
|
- Dana-Farber Cancer Insitute
Boston, Massachusetts, United States
|
|
| 7 |
NCT00165425 |
Active, not recruiting |
Cardiac Screening in Survivors of Hodgkin's Disease Treated With Mediastinal Irradiation |
|
- Procedure: Echo/Stress Echo
|
Interventional
|
Not Applicable |
- Dana-Farber Cancer Institute
- Brigham and Women's Hospital
- Dana-Farber Cancer Institute
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- To determine the feasibility of a cardiac screening program in patients who are 5 to 10 years our from initial mediastinal irradiation for Hodgkin's disease.
- To prospectively collect data on the prevalence of modifiable cardiac risk factors and the spectrum of cardiac structural abnormalities in this patient populations
- to correlate cardiac structural abnormalities with quality of life
- to correlate cardiac structural abnormalities with level of fatigue.
|
210 |
All |
20 Years and older (Adult, Older Adult) |
NCT00165425 |
03-295 |
|
February 2004 |
October 2007 |
April 2018 |
September 14, 2005 |
July 28, 2017 |
|
- Brigham and Women's Hospital
Boston, Massachusetts, United States - Dana-Farber Cancer Institute
Boston, Massachusetts, United States
|
|
| 8 |
NCT00601146 |
Active, not recruiting
Has Results |
Low-Dose Chest Computed Tomography Screening for Lung Cancer in Survivors of Hodgkin's Disease |
|
- Procedure: chest computed tomography scan
|
Observational
|
|
- Dana-Farber Cancer Institute
- Brigham and Women's Hospital
- Dana-Farber Cancer Institute
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- To Prospectively Collect Data on Chest CT Screening for Patients at Increase Lung-cancer Risk After Hodgkin's Disease.
|
39 |
All |
18 Years and older (Adult, Older Adult) |
NCT00601146 |
06-122 |
|
November 2006 |
December 2010 |
December 2018 |
January 25, 2008 |
August 24, 2017 |
February 17, 2016 |
- Brigham and Women's Hospital
Boston, Massachusetts, United States - Dana-Farber Cancer Institute
Boston, Massachusetts, United States
|
|
| 9 |
NCT00815919 |
Completed
Has Results |
Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft Versus Host Disease |
- Chronic Graft Versus Host Disease
|
- Drug: bortezomib
- Drug: Prednisone
|
Interventional
|
Phase 2 |
- Dana-Farber Cancer Institute
- Millennium Pharmaceuticals, Inc.
- Dana-Farber Cancer Institute
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Response Rate After a 15 Week Course of Bortezomib Plus Prednisone in Patients With cGVHD
- Proportion of Patients Tolerating >50% Steroid Dose Reduction After a 15 Week Course of Bortezomib Plus Prednisone in Patients With cGVHD
- The Toxicity of a 15 Week Course of Bortezomib Plus Prednisone in Patients With cGVHD
- (and 2 more...)
|
22 |
All |
18 Years and older (Adult, Older Adult) |
NCT00815919 |
08-191 |
|
December 2008 |
January 2012 |
January 2013 |
December 31, 2008 |
July 22, 2015 |
February 28, 2014 |
- Dana-Farber Cancer Institute
Boston, Massachusetts, United States
|
|
| 10 |
NCT02867384 |
Recruiting |
A Study of Obinutuzumab for Prevention of Chronic Graft-vs.-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation |
|
- Drug: Obinutuzumab
- Drug: Placebo
|
Interventional
|
Phase 2 |
- Dana-Farber Cancer Institute
- Roche/Genentech Inc.
- Dana-Farber Cancer Institute
|
Other |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- The Rate Of Corticosteroid-Requiring cGVHD At One Year From HCT
- Overall cGVHD Rate After HCT
- Immunosuppression-Free Survival (IFS) Rate
- (and 2 more...)
|
200 |
All |
18 Years and older (Adult, Older Adult) |
NCT02867384 |
16-256 |
|
November 29, 2016 |
February 2020 |
February 2024 |
August 15, 2016 |
January 12, 2018 |
|
- Stanford University
Palo Alto, California, United States - Massachusetts General Hospital
Boston, Massachusetts, United States - Dana Farber Cancer Institute
Boston, Massachusetts, United States
|
|
| 11 |
NCT00165412 |
Completed |
Breast MRI Screening in Women Treated With Mediastinal Irradiation for Hodgkin's Disease |
- Breast Cancer
- Hodgkin's Disease
|
- Procedure: breast MRI
- Procedure: Mammogram
|
Observational
|
|
- Dana-Farber Cancer Institute
- Brigham and Women's Hospital
- Beth Israel Deaconess Medical Center
- Dana-Farber Cancer Institute
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- To compare the sensitivity, specificity, positive and negative predictive value of mammography and breast MRI for breast cancer detection in women treated for Hodgkin's disease.
- To describe the MRI appearance and enhancing characteristics of breast cancer after Hodgkin's disease
- to correlate the breast MRI findings and pathological findings
- to determine the incidence of interval breast cancer in the screened population.
|
168 |
Female |
20 Years and older (Adult, Older Adult) |
NCT00165412 |
05-241 |
|
July 2005 |
May 2010 |
May 2010 |
September 14, 2005 |
August 14, 2012 |
|
- Brigham and Women's Hospital
Boston, Massachusetts, United States - Dana-Farber Cancer Center
Boston, Massachusetts, United States - Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
|
|
| 12 |
NCT00529035 |
Active, not recruiting
Has Results |
Ultra-Low Dose Interleukin-2 for Refractory Chronic Graft Versus Host Disease |
- Graft Versus Host Disease
|
|
Interventional
|
Phase 1 |
- Dana-Farber Cancer Institute
- Brigham and Women's Hospital
- Novartis
- Dana-Farber Cancer Institute
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The Maximum Tolerated Dose and Toxicity Profile of an 8 Week Course of IL-2 in Patients With cGVHD and an Inadequate Response to Steroids.
- The Number of Participants Who Tolerated at Least 6 Weeks of Subcutaneous Low Dose IL-2.
- CD3+T, CD4+T (Including Regulatory CD4+T Cells (Treg) and Conventional CD4+T Cells (Tcon)), CD8+T, NK, NKT and B Cell Counts.
- Treg Cell:Tcon Cell Ratio
|
29 |
All |
18 Years and older (Adult, Older Adult) |
NCT00529035 |
07-083 |
|
August 2007 |
June 2011 |
August 2018 |
September 14, 2007 |
November 6, 2017 |
January 29, 2014 |
- Dana-Farber Cancer Institute
Boston, Massachusetts, United States
|
|
| 13 |
NCT02880319 |
Not yet recruiting |
Phase II Protocol Evaluating Stereotactic Body Radiation Therapy for Oligometastatic Disease of the Bone |
|
- Drug: Stereotactic Body Radiation Therapy (SBRT)
- Device: Stereotactic Linear Accelerator
|
Interventional
|
Phase 2 |
- Dana-Farber Cancer Institute
- Dana-Farber Cancer Institute
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Evaluate The Local Control Rate Of SBRT
- Local Progression-Free Survival
- Progression-Free Survival
- (and 3 more...)
|
100 |
All |
18 Years and older (Adult, Older Adult) |
NCT02880319 |
16-207 |
|
September 2016 |
March 2020 |
March 2024 |
August 26, 2016 |
August 26, 2016 |
|
- Dana Farber Cancer Institute
Boston, Massachusetts, United States
|
|
| 14 |
NCT01366092 |
Active, not recruiting
Has Results |
Daily IL-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease |
- Chronic Graft-versus-host Disease
|
|
Interventional
|
Phase 2 |
- Dana-Farber Cancer Institute
- National Cancer Institute (NCI)
- Prometheus Laboratories
- Dana-Farber Cancer Institute
|
Other / NIH / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Response Rate of Low-dose Daily SC IL-2 in Steroid-refractory cGVHD
- Toxicity of 12-week Course of Low-dose SC IL-2 Therapy
- Prednisone Taper With IL-2 Therapy
- (and 3 more...)
|
35 |
All |
18 Years and older (Adult, Older Adult) |
NCT01366092 |
11-149
P01CA142106 |
|
July 2011 |
October 2014 |
August 2018 |
June 3, 2011 |
November 6, 2017 |
January 15, 2015 |
- Dana-Farber Cancer Institute
Boston, Massachusetts, United States - Massachusetts General Hospital
Boston, Massachusetts, United States - Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
|
|
| 15 |
NCT00136396 |
Completed |
Rituximab Therapy for Steroid-Refractory Chronic Graft Versus Host Disease |
|
|
Interventional
|
Phase 1
Phase 2 |
- Dana-Farber Cancer Institute
- Brigham and Women's Hospital
- Dana-Farber Cancer Institute
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To determine the safety and efficacy of up to three four week courses of rituximab in steroid-refractory chronic GVHD
- To determine the effects of rituximab therapy on quality of life of patients with steroid-refractory GVHD
|
30 |
All |
18 Years and older (Adult, Older Adult) |
NCT00136396 |
03-120 |
|
January 2004 |
November 2006 |
November 2010 |
August 29, 2005 |
June 12, 2013 |
|
- Brigham and Women's Hospital
Boston, Massachusetts, United States - Dana-Farber Cancer Institute
Boston, Massachusetts, United States
|
|
| 16 |
NCT00165308 |
Completed |
Tamoxifen in the Prevention of Breast Cancer in Hodgkin's Disease Survivors |
- Hodgkin's Disease
- Breast Cancer
|
|
Interventional
|
Not Applicable |
- Dana-Farber Cancer Institute
- Brigham and Women's Hospital
- Massachusetts General Hospital
- (and 2 more...)
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- To determine the feasibility of a randomized trial testing the effectiveness of tamoxifen in reducing the risk of radiogenic breast cancer.
- To determine the safety and effect on quality of life in participating women.
|
29 |
Female |
18 Years to 35 Years (Adult) |
NCT00165308 |
00-253 |
|
April 2001 |
March 2004 |
June 2009 |
September 14, 2005 |
July 9, 2014 |
|
- Massachusetts General Hospital
Boston, Massachusetts, United States - Dana-Farber Cancer Institute
Boston, Massachusetts, United States
|
|
| 17 |
NCT00369226 |
Completed
Has Results |
Bortezomib Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease (GVHD) After Mismatched Allogeneic Non-Myeloablative Blood Stem Cell Transplantation |
|
- Drug: Bortezomib (Velcade)
- Drug: Tacrolimus
- Drug: Methotrexate
- Procedure: blood stem cell transplantation
|
Interventional
|
Phase 1
Phase 2 |
- Dana-Farber Cancer Institute
- Brigham and Women's Hospital
- Millennium Pharmaceuticals, Inc.
- Dana-Farber Cancer Institute
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- The Maximally Tolerated Dose (MTD) of Bortezomib (Velcade) That Can be Administered With Tacrolimus and Methotrexate After Mismatched Allogeneic Non-myeloablative Peripheral Blood Stem Cell (PBSC) Transplantation
- Successful Initial Engraftment by Day 45 Post Peripheral Blood Stem Cell (PBSC) Infusion and Administration of Bortezomib (Velcade), Tacrolimus and Methotrexate
- Incidence of Grade II-IV Acute Graft Versus Host Disease (GVHD) by Day 100.
- (and 3 more...)
|
45 |
All |
18 Years and older (Adult, Older Adult) |
NCT00369226 |
06-065
X05175 |
|
August 2006 |
July 2010 |
September 2011 |
August 29, 2006 |
July 25, 2013 |
July 25, 2013 |
- Brigham and Women's Hospital
Boston, Massachusetts, United States - Dana-Farber Cancer Institute
Boston, Massachusetts, United States
|
|
| 18 |
NCT01937468 |
Active, not recruiting |
Trial of Regulatory T-cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease |
- Chronic Graft Versus Host Disease
- Chronic GVHD
- Complications of Organ Transplant Stem Cells
|
- Other: Treg-enriched infusion
- Drug: Interleukin-2
|
Interventional
|
Phase 1 |
- Dana-Farber Cancer Institute
- Miltenyi Biotec GmbH
- Prometheus Laboratories
- (and 2 more...)
|
Other / Industry / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Adverse event profile and the maximum tolerate dose of Treg-enriched infusion plus 8-week low-dose IL-2
- To determine feasibility of Treg-enriched infusion plus 8-week low-dose IL-2
- Clinical response of cGVHD as defined by the NIH consensus criteria to Treg-enriched infusion plus 8-week low-dose IL-2
- Expansion of Treg cells in the peripheral blood after a Treg-enriched infusion plus 8-week low-dose IL-2
|
25 |
All |
18 Years and older (Adult, Older Adult) |
NCT01937468 |
13-281
R01CA183559-01 |
|
November 2013 |
August 2017 |
November 2020 |
September 9, 2013 |
January 26, 2018 |
|
- Brigham and Women's Hospital
Boston, Massachusetts, United States - Dana-Farber Cancer Insitute
Boston, Massachusetts, United States
|
|
| 19 |
NCT00282282 |
Completed
Has Results |
Tacrolimus and Sirolimus as Prophylaxis After Allogenic Non-myeloablative Peripheral Blood Stem Cell Transplantation |
- Graft Versus Host Disease
- GVHD
|
- Drug: tacrolimus
- Drug: sirolimus
- Drug: fludarabine
- Drug: busulfex
|
Interventional
|
Phase 2 |
- Dana-Farber Cancer Institute
- Brigham and Women's Hospital
- Dana-Farber Cancer Institute
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of Grade II-IV Acute GVHD (aGVHD) Developing by Day 100 Following Non-myeloablative PBSC Transplantation Using Tacrolimus and Sirolimus.
- Percentage of Participants With ≥90 Percent Donor-derived Hematopoeisis Around 100 Days Post Transplantation
- Disease Response.
|
31 |
All |
18 Years and older (Adult, Older Adult) |
NCT00282282 |
05-362 |
|
January 2006 |
January 2009 |
July 2009 |
January 26, 2006 |
May 12, 2014 |
April 8, 2014 |
- Dana-Farber Cancer Institute
Boston, Massachusetts, United States
|
|
| 20 |
NCT00548717 |
Terminated
Has Results |
Sirolimus, Mycophenolate Mofetil and Bortezomib as Graft-Versus-Host Disease (GVHD) Prophylaxis After Reduced Intensity Conditioning (RIC) Hematopoietic Stem Cell Transplantation |
|
- Drug: Sirolimus
- Drug: Mycophenolate mofetil
- Drug: Bortezomib
|
Interventional
|
Phase 2 |
- Dana-Farber Cancer Institute
- Wyeth is now a wholly owned subsidiary of Pfizer
- PDL BioPharma, Inc.
- Dana-Farber Cancer Institute
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- To Determine the Rate of Grade II-IV Acute GVHD When Sirolimus and Mycophenolate Mofetil or Sirolimus, Mycophenolate Mofetil and Bortezomib is Used for GVHD Prophylaxis After Allogeneic Stem Cell Transplantation in Patients With Hematologic Malignancies
- Donor Stem Cell Engraftment, Including Donor-host Hematopoietic Chimerism Studies Post Transplant
- The Rate of Renal Insufficiency
- (and 4 more...)
|
15 |
All |
18 Years and older (Adult, Older Adult) |
NCT00548717 |
DFCI 07-197 |
|
October 2007 |
September 2013 |
September 2013 |
October 24, 2007 |
October 21, 2014 |
October 21, 2014 |
- Dana-Farber Cancer Institute
Boston, Massachusetts, United States
|
|
| 21 |
NCT00495755 |
Completed
Has Results |
Campath in Chronic GVHD |
- Chronic Graft-vs.-Host Disease
|
- Drug: Alemtuzumab (Campath)
|
Interventional
|
Phase 1 |
- Dana-Farber Cancer Institute
- Genzyme, a Sanofi Company
- Bayer
- Dana-Farber Cancer Institute
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The Maximum Tolerated Dose (MTD) of a Four-week Course of Alemtuxumab in Chronic GVHD for Patients With an Incomplete Response to Steroids
- The Efficacy of a Four-week Course of Alemtuzumab in Patients With Steroid-refractory Chronic GVHD (cGVHD).
- The Effect of Alemtuzumab Therapy on Parameters of Cellular and Humoral Immunity in the Late Post Transplant Period. This Information is Exploratory in Nature Only Due to the Heterogeneity of the Anticipated Patient Population.
|
13 |
All |
18 Years and older (Adult, Older Adult) |
NCT00495755 |
DFCI 07-057 |
|
July 2007 |
October 2011 |
October 2012 |
July 3, 2007 |
August 9, 2013 |
August 9, 2013 |
- Dana-Farber Cancer Institute
Boston, Massachusetts, United States
|
|
| 22 |
NCT01754389 |
Completed
Has Results |
Standard of Care vs. Bortezomib in Graft-Versus Host Disease After Hematopoietic Stem Cell Transplant |
- Graft Versus Host Disease
|
- Drug: Tacrolimus
- Drug: Methotrexate
- Drug: Bortezomib
- Drug: Sirolimus
|
Interventional
|
Phase 2 |
- Dana-Farber Cancer Institute
- Dana-Farber Cancer Institute
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of Participants With Incidence of Grade II-IV GVHD
- Percentage of Participants With Non-relapse Mortality
- Percentage of Participants With Relapse
- (and 2 more...)
|
138 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT01754389 |
12-404 |
|
January 2013 |
May 2016 |
November 2016 |
December 21, 2012 |
July 18, 2017 |
July 18, 2017 |
- Massachusetts General Hospital
Boston, Massachusetts, United States - Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States - Brigham and Women's Hospital
Boston, Massachusetts, United States - Dana-Farber Cancer Insitute
Boston, Massachusetts, United States
|
|
| 23 |
NCT00003966 |
Completed |
Defibrotide in Treating Patients With Liver Damage Following Peripheral Stem Cell Transplantation |
|
|
Interventional
|
Phase 2 |
- Dana-Farber Cancer Institute
- Jazz Pharmaceuticals
- National Cancer Institute (NCI)
- Dana-Farber Cancer Institute
|
Other / Industry / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Complete Response Rate as measured by a total bilirubin of < 2 mg/dL and resolution of multi-organ failure attributable to veno-occlusive disease (VOD)
- Survival at 100 days following stem cell transplantation
- Toxicity by NCI Common Toxicity Criteria version 2.0 during study and 30 days after study completion
- (and 4 more...)
|
151 |
All |
up to 18 Years (Child, Adult) |
NCT00003966 |
99118
P30CA015704
DFCI-1999-P-010076/14
DUMC-00176-00-2
FHCRC-1375.00
NCI-G99-1548
CHNMC-02118
MSKCC-03-058
JHMI-00-06-02-02 |
|
April 2000 |
February 2006 |
April 2006 |
January 27, 2003 |
January 20, 2017 |
|
- City of Hope Comprehensive Cancer Center
Duarte, California, United States - Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, United States - Children's Hospital Boston
Boston, Massachusetts, United States - (and 6 more...)
|
|
| 24 |
NCT01226420 |
Terminated
Has Results |
Alefacept in Subjects With Steroid-Refractory Chronic Graft-versus-Host Disease |
- Chronic Graft-versus-host Disease
|
|
Interventional
|
Phase 2 |
- Dana-Farber Cancer Institute
- Brigham and Women's Hospital
- Astellas Pharma Inc
- Dana-Farber Cancer Institute
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Efficacy
- Safety of Alefacept Infusions in Patients With Chronic GVHD.
|
6 |
All |
18 Years and older (Adult, Older Adult) |
NCT01226420 |
10-230 |
|
October 2010 |
August 2012 |
August 2012 |
October 22, 2010 |
August 13, 2013 |
August 13, 2013 |
- Dana-Farber Cancer Institute
Boston, Massachusetts, United States - Fred Hutch Cancer Research Center
Seattle, Washington, United States - Medical College of Wisconsin
Milwaukee, Wisconsin, United States
|
|
| 25 |
NCT00146614 |
Completed |
Tacrolimus, Sirolimus and Methotrexate as Graft Versus Host Disease Prophylaxis After Blood Stem Cell Transplantation |
- Graft Versus Host Disease
- Hematologic Malignancies
|
- Drug: Sirolimus
- Drug: Tacrolimus
- Drug: Methotrexate
- Procedure: Stem Cell Transplantation
|
Interventional
|
Phase 2 |
- Dana-Farber Cancer Institute
- Brigham and Women's Hospital
- Beth Israel Deaconess Medical Center
- (and 2 more...)
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To assess the effect on the incidence and severity of GVHD by adding sirolimus, tacrolimus and methotrexate to GVHD prophylaxis.
|
105 |
All |
18 Years and older (Adult, Older Adult) |
NCT00146614 |
02-057 |
|
July 2002 |
April 2003 |
April 2003 |
September 7, 2005 |
March 8, 2012 |
|
- Beth Isreal Deaconess Medical Center
Boston, Massachusetts, United States - Dana-Farber Cancer Institute
Boston, Massachusetts, United States - Massachusetts General Hospital
Boston, Massachusetts, United States
|
|
| 26 |
NCT02523040 |
Recruiting |
A Study of Lenalidomide for Adult Histiocyte Disorders |
- Langerhans Cell Histiocytosis (LCH)
- Histiocytoses Erdheim-chester Disease
- Histiocytic Sarcoma (HS)
|
|
Interventional
|
Phase 2 |
- Dana-Farber Cancer Institute
- Celgene
- Dana-Farber Cancer Institute
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Response Rate
- Progression Free Survival (PFS)
- Overall Survival
- (and 4 more...)
|
12 |
All |
18 Years and older (Adult, Older Adult) |
NCT02523040 |
15-197 |
|
August 2015 |
August 2018 |
August 2022 |
August 14, 2015 |
June 2, 2017 |
|
- Dana-Farber Cancer Institute
Boston, Massachusetts, United States
|
|
| 27 |
NCT02123966 |
Terminated |
An Open Label Phase II Trial of Topical Sirolimus for the Treatment of Refractory Oral Chronic Graft-versus-Host-Disease |
- Chronic Graft-versus-Host-Disease
- Oral Mucosal Disease Due to Graft-versus-host Disease
|
|
Interventional
|
Phase 2 |
- Dana-Farber Cancer Institute
- Dana-Farber Cancer Institute
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Percentage of Participants with a Subjective Sensitivity Score Response
- Oral Health QOL Assessment
|
10 |
All |
4 Years and older (Child, Adult, Older Adult) |
NCT02123966 |
14-090 |
|
May 2014 |
December 30, 2016 |
December 30, 2016 |
April 28, 2014 |
January 31, 2018 |
|
- Brigham and Women's Hospital
Boston, Massachusetts, United States - Dana-Farber Cancer Institute
Boston, Massachusetts, United States
|
|
| 28 |
NCT00053976 |
Completed |
Methylprednisolone With or Without Daclizumab in Treating Patients With Acute Graft-Versus-Host Disease |
- Graft Versus Host Disease
|
- Biological: Daclizumab
- Drug: methylprednisolone
- Drug: Placebo
|
Interventional
|
Phase 3 |
- Dana-Farber Cancer Institute
- National Cancer Institute (NCI)
- Dana-Farber Cancer Institute
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Rate of decrease of acute GVHD grade
- 100 Day Mortality
- Complete Response of GVHD
- (and 6 more...)
|
105 |
All |
18 Years and older (Adult, Older Adult) |
NCT00053976 |
99-279
P30CA016056
P30CA006516
RPCI-DS-0218
ROCHE-RPCI-DS-0218 |
|
January 2001 |
November 2003 |
November 2004 |
February 6, 2003 |
January 23, 2017 |
|
- Massachusetts General Hospital
Boston, Massachusetts, United States - Brigham and Women's Hospital
Boston, Massachusetts, United States - Dana Farber Cancer Institute
Boston, Massachusetts, United States - (and 5 more...)
|
|
| 29 |
NCT00165438 |
Completed |
Pulmonary Function in Patients With Hodgkin's Disease Receiving Bleomycin-Based Chemotherapy |
|
- Procedure: Pulmonary Function Tests
- Procedure: CAT Scan
|
Observational
|
|
- Dana-Farber Cancer Institute
- Brigham and Women's Hospital
- Dana-Farber Cancer Institute
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
|
60 |
All |
18 Years and older (Adult, Older Adult) |
NCT00165438 |
01-181 |
|
October 2001 |
November 2005 |
January 2010 |
September 14, 2005 |
December 20, 2012 |
|
- Brigham and Women's Hospital
Boston, Massachusetts, United States - Dana-Farber Cancer Institute
Boston, Massachusetts, United States
|
|
| 30 |
NCT00144703 |
Completed |
Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Related Stem Cell Transplantation |
- Hematologic Malignancies
- Myelogenous Leukemia
- Acute Lymphoblastic Leukemia
- (and 3 more...)
|
- Drug: Sirolimus
- Drug: Tacrolimus
|
Interventional
|
Phase 2 |
- Dana-Farber Cancer Institute
- Brigham and Women's Hospital
- Dana-Farber Cancer Institute
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- To determine the feasibility of using sirolimus and tacrolimus without methotrexate for GVHD prophylaxis after stem cell transplantation.
- To compare the rates of grade II-IV and III-IV acute GVHD with historical controls
- to determine the incidence of 100 day mortality after stem cell transplant using this regimen
- to determine the overall survival at 1 year after transplantation in this patient population.
|
55 |
All |
18 Years and older (Adult, Older Adult) |
NCT00144703 |
02-090 |
|
July 2002 |
November 2006 |
November 2006 |
September 5, 2005 |
January 26, 2012 |
|
- Dana-Farber Cancer Institute
Boston, Massachusetts, United States
|
|
| 31 |
NCT00144677 |
Completed |
Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell Transplantation |
- Acute Myelogenous Leukemia
- Graft Versus Host Disease
- Acute Lymphoblastic Leukemia
- (and 4 more...)
|
- Drug: sirolimus
- Drug: tacrolimus
|
Interventional
|
Phase 2 |
- Dana-Farber Cancer Institute
- Dana-Farber Cancer Institute
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- To determine the feasibility of using a combination of sirolimus and tacrolimus without methotrexate for GVHD prophylaxis after stem cell transplantation.
- To compare the rates of grade II-IV and III-IV acute GVHD with historical control
- to determine the incidence of 100 day mortality using this GVHD prophylaxis regimen
- to determine the overall survival after one year of this patient population.
|
30 |
All |
18 Years to 55 Years (Adult) |
NCT00144677 |
03-290 |
|
November 2003 |
June 2006 |
June 2006 |
September 5, 2005 |
January 26, 2012 |
|
- Dana-Farber Cancer Center
Boston, Massachusetts, United States
|
|
| 32 |
NCT01221766 |
Completed |
Impact of Adnexal Involvement of the Severity and Prognosis of Chronic Graft-versus-Host Disease |
- Graft vs Host Disease
- Chronic Graft vs Host Disease
- cGVHD
|
|
Observational
|
|
- Dana-Farber Cancer Institute
- Dana-Farber Cancer Institute
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
|
12 |
All |
Child, Adult, Older Adult |
NCT01221766 |
10-163 |
|
September 2010 |
April 2013 |
October 2014 |
October 15, 2010 |
March 31, 2015 |
|
- Children's Hospital Boston
Boston, Massachusetts, United States - Dana-Farber Cancer Institute
Boston, Massachusetts, United States
|
|
| 33 |
NCT01085201 |
Completed
Has Results |
Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease |
|
|
Interventional
|
Phase 1 |
- Dana-Farber Cancer Institute
- Brigham and Women's Hospital
- Boston Children’s Hospital
- (and 7 more...)
|
Other / NIH / Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Dose Limiting Toxicities as a Measure of Whether Infusional Lexiscan is Safe in Individuals With SCD.
- Percentage of Activated iNKT Cells and/or Activation Markers on iNKT Cells in Individuals With SCD.
- Pain Levels During a Vaso-occlusive Event in Children and Adults With SCD.
|
39 |
All |
10 Years to 70 Years (Child, Adult, Older Adult) |
NCT01085201 |
09-308
1RC2HL101367-01 |
|
April 2010 |
February 2013 |
March 2013 |
March 11, 2010 |
March 7, 2014 |
March 7, 2014 |
- Howard University Hospital
Washington, District of Columbia, United States - Johns Hopkins University
Baltimore, Maryland, United States - Brigham and Women's Hospital
Boston, Massachusetts, United States - (and 4 more...)
|
|
| 34 |
NCT00136409 |
Completed |
A Study of Gleevec in Patients With Idiopathic Myelofibrosis or Chronic Myelomonocytic Leukemia (CMML) |
- Myelofibrosis
- Myeloid Metaplasia
- Agnogenic Myeloid Metaplasia
- Chronic Myelomonocytic Leukemia
|
|
Interventional
|
Phase 2 |
- Dana-Farber Cancer Institute
- Brigham and Women's Hospital
- Massachusetts General Hospital
- (and 2 more...)
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To determine the overall response rate of Gleevec as a single agent in patients with BCR-negative myeloproliferative disorders including myelofibrosis with myeloid metaplasia and chronic myelomonocytic leukemia
- To determine the safety and efficacy of Gleevec as a single agent in patients with BCR-negative myeloproliferative disorders including myelofibrosis with myeloid metaplasia or chronic myelomonocytic leukemia
- to determine the biologic activity of Gleevec in patients with BCR-negative myeloproliferative disorders including myelofibrosis with myeloid metaplasia or chronic myelomonocytic leukemia
|
34 |
All |
18 Years and older (Adult, Older Adult) |
NCT00136409 |
01-214 |
|
May 2002 |
August 2005 |
December 2008 |
August 29, 2005 |
December 23, 2016 |
|
- Dana-Farber Cancer Institute
Boston, Massachusetts, United States - Massachusetts General Hospital
Boston, Massachusetts, United States
|
|
| 35 |
NCT01858688 |
Active, not recruiting |
A Phase II, Prospective Study of MRI in the Reclassification of Men Considering Active Surveillance in Prostate Cancer |
|
- Device: Multiparametric MRI
- Procedure: Prostate biopsy
|
Interventional
|
Not Applicable |
- Dana-Farber Cancer Institute
- Dana-Farber Cancer Institute
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Number of participants who have an MP-erMRI finding suggestive of more aggressive disease relative to repeat 12 core TRUS biopsy
- Number of men who have an MP-erMRIs which appear to reclassify them to more extensive or aggressive disease
- Number of participants to report a change in their health status following the MP-erMRI and rebiopsy o
- Report on the tumor grade and extent from the targeted biopsy relative to findings on the MP-erMRI
|
130 |
Male |
18 Years and older (Adult, Older Adult) |
NCT01858688 |
13-056 |
|
June 2013 |
May 2018 |
December 2018 |
May 21, 2013 |
February 1, 2018 |
|
- Brigham and Women's Hospital
Boston, Massachusetts, United States - Dana Farber Cancer Institute
Boston, Massachusetts, United States
|
|
| 36 |
NCT01177527 |
Recruiting |
Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders |
- Multiple Myeloma
- Waldenstrom's Macroglobulinemia
- Smoldering Multiple Myeloma
- Lymphoblastic Lymphoma
|
|
Observational
|
|
- Dana-Farber Cancer Institute
- Dana-Farber Cancer Institute
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Databank
- Unique characteristics
|
1000 |
All |
18 Years and older (Adult, Older Adult) |
NCT01177527 |
09-233 |
|
December 2009 |
December 2018 |
December 2020 |
August 9, 2010 |
October 16, 2017 |
|
- Dana-Farber Cancer Institute
Boston, Massachusetts, United States
|
|
| 37 |
NCT03532971 |
Not yet recruiting |
Prospective Study of BK Virus Disease After Allogeneic Hematopoietic-cell Transplantation: Defining BK Disease's Natural History, Clinical Spectrum, Immunology, and Outcomes |
|
- Other: Symptom index questionnaire
- Diagnostic Test: BK polyomavirus PCR
- Other: quality of life questionnaires
|
Observational
|
|
- Dana-Farber Cancer Institute
- Dana-Farber Cancer Institute
|
Other |
- Observational Model: Cohort
- Time Perspective: Other
|
- The mean total number of cytokine producing BKV-specific NK and T-cells at the time of BKVD in affected patients, as compared with unaffected patients
- Analytically determine a BKV-specific cfDNA methylation pattern in the urine and plasma samples of affected patients
- Analytically determine BKV-specific antibody glycosylation patterns in plasma samples of patients who exhibit BKVR.
|
125 |
All |
18 Years and older (Adult, Older Adult) |
NCT03532971 |
17-664 |
|
May 11, 2018 |
December 31, 2019 |
June 30, 2024 |
May 22, 2018 |
May 22, 2018 |
|
- Dana-Farber Cancer Institute
Boston, Massachusetts, United States
|
|
| 38 |
NCT00333190 |
Completed |
CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation |
- Hematologic Malignancy
- AML
- ALL
- (and 4 more...)
|
- Device: CD+8 T cell depletion
|
Interventional
|
Not Applicable |
- Dana-Farber Cancer Institute
- Brigham and Women's Hospital
- Dana-Farber Cancer Institute
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- To assess the initial engraftment of HLA matched unrelated donor mobilized peripheral blood stem cells depleted of CD+8 cells.
- To assess sustained engraftment
- to determine the incidence of GVHD
- to assess disease relapse.
|
30 |
All |
18 Years and older (Adult, Older Adult) |
NCT00333190 |
05-151 |
|
September 2005 |
March 2007 |
March 2009 |
June 2, 2006 |
March 16, 2012 |
|
- Brigham and Women's Hospital
Boston, Massachusetts, United States - Dana-Farber Cancer Institute
Boston, Massachusetts, United States
|
|
| 39 |
NCT01000155 |
Terminated
Has Results |
Efficacy of Vorinostat to Induce Fetal Hemoglobin in Sickle Cell Disease |
- Sickle Cell Disease
- Sickle Cell Anemia
|
|
Interventional
|
Phase 2 |
- Dana-Farber Cancer Institute
- Brigham and Women's Hospital
- Boston Children’s Hospital
- (and 2 more...)
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percent Fetal Hemoglobin (HbF%) Induction Success Rate
- F-Cell Percentage Level
- γ-globin to β-globin Ratio
|
5 |
All |
18 Years and older (Adult, Older Adult) |
NCT01000155 |
09-237 |
|
October 2009 |
October 2014 |
October 2014 |
October 22, 2009 |
July 21, 2017 |
October 8, 2015 |
- Brigham and Women's Hospital
Boston, Massachusetts, United States - Children's Hospital Boston
Boston, Massachusetts, United States - Dana-Farber Cancer Institute
Boston, Massachusetts, United States
|
|
| 40 |
NCT02641236 |
Recruiting |
Gut Decontamination In Pediatric Allogeneic Hematopoietic |
- Hematopoietic Stem Cell Transplantation (HSCT)
- Acute GVH Disease
|
- Drug: Vancomycin-polymyxin B
|
Interventional
|
Phase 2 |
- Dana-Farber Cancer Institute
- Dana-Farber Cancer Institute
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Gut Microbiome Description
- Stool Frequency
- Immune cell profiling: Absolute cell numbers of T-, B-, NK- and dendritic cell subsets by flow cytometry
- (and 3 more...)
|
28 |
All |
4 Years to 30 Years (Child, Adult) |
NCT02641236 |
15-394 |
|
March 2016 |
October 2019 |
May 2023 |
December 29, 2015 |
July 19, 2017 |
|
- Boston Children's Hospital
Boston, Massachusetts, United States - Dana-Farber Cancer Institute
Boston, Massachusetts, United States
|
|
| 41 |
NCT00409292 |
Completed
Has Results |
RAD001 in Previously Treated Patients With Metastatic Pancreatic Cancer |
|
|
Interventional
|
Phase 2 |
- Dana-Farber Cancer Institute
- Massachusetts General Hospital
- Beth Israel Deaconess Medical Center
- (and 2 more...)
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To Assess Progression-free Survival of RAD001 at Two Months in Patients With Metastatic Pancreatic Cancer Whose Disease Has Progressed on Gemcitabine Chemotherapy.
- To Assess the Safety of RAD001 in Patients With Metastatic Pancreatic Cancer
- to Assess Response Rate Associated With RAD001 in This Patient Population.
- to Assess Overall Survival Associated With RAD001 in This Patient Population.
|
33 |
All |
18 Years and older (Adult, Older Adult) |
NCT00409292 |
06-197 |
|
January 2007 |
January 2009 |
May 2009 |
December 8, 2006 |
August 11, 2014 |
August 11, 2014 |
- Massachusetts General Hospital
Boston, Massachusetts, United States - Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States - Dana-Farber Cancer Institute
Boston, Massachusetts, United States
|
|
| 42 |
NCT00379587 |
Completed
Has Results |
Rituximab for Prevention of Chronic GVHD |
- Hematological Malignancies
|
- Drug: Rituximab
- Drug: 375 mg/m2 RRituximab
|
Interventional
|
Phase 1
Phase 2 |
- Dana-Farber Cancer Institute
- Genentech, Inc.
- Biogen
- Dana-Farber Cancer Institute
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Incidence of Clinician-diagnosed Chronic GVHD at One and Two Years
- Incidence of Grade 3 or Higher Infectious Complications
- Incidence of Relapse or Progression of Disease
- Incidence of Adverse Hematological Events
|
65 |
All |
18 Years and older (Adult, Older Adult) |
NCT00379587 |
05-377 |
|
September 2006 |
August 2012 |
August 2012 |
September 22, 2006 |
March 19, 2014 |
March 19, 2014 |
- Dana-Farber Cancer Institute
Boston, Massachusetts, United States
|
|
| 43 |
NCT01551693 |
Terminated
Has Results |
STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV Melanoma |
|
|
Interventional
|
Phase 2 |
- Dana-Farber Cancer Institute
- Synta Pharmaceuticals Corp.
- Dana-Farber Cancer Institute
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- 6-month Progression-Free Survival Rate
- Best Overall Response
- Overall Survival
|
3 |
All |
18 Years and older (Adult, Older Adult) |
NCT01551693 |
11-039 |
|
September 2011 |
September 2012 |
September 2012 |
March 13, 2012 |
April 12, 2017 |
April 12, 2017 |
- Dana-Farber Cancer Institute
Boston, Massachusetts, United States
|
|
| 44 |
NCT00424515 |
Completed
Has Results |
Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma |
- Mucosal Melanoma
- Acral/Lentiginous Melanoma
- Chronically Sun Damaged Melanomas
|
|
Interventional
|
Phase 2 |
- Dana-Farber Cancer Institute
- Novartis
- Dana-Farber Cancer Institute
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Best Overall Response
- Time to Progression
- Overall Survival
|
24 |
All |
18 Years and older (Adult, Older Adult) |
NCT00424515 |
06-056 |
BUS255 |
July 2006 |
July 2011 |
July 2011 |
January 19, 2007 |
December 8, 2016 |
December 8, 2016 |
- University of Colorado at Denver Health Sciences Center
Denver, Colorado, United States - H. Lee Moffitt Cancer Center
Tampa, Florida, United States - University of Chicago
Chicago, Illinois, United States - (and 2 more...)
|
|
| 45 |
NCT00301093 |
Active, not recruiting |
Vaccine Therapy and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia |
|
- Biological: GM-K562 cell vaccine
- Drug: imatinib mesylate
|
Interventional
|
Phase 1 |
- Dana-Farber Cancer Institute
- National Cancer Institute (NCI)
- Beth Israel Deaconess Medical Center
- Dana-Farber Cancer Institute
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety and Toxicity
- Disease Response
- Tumor immunity
|
30 |
All |
18 Years and older (Adult, Older Adult) |
NCT00301093 |
04-126
R21CA115043
P30CA006516
CDR0000456445 |
|
September 2005 |
May 2007 |
January 1, 2019 |
March 10, 2006 |
February 1, 2018 |
|
- Dana Farber Cancer Institute
Boston, Massachusetts, United States
|
|
| 46 |
NCT00098865 |
Completed
Has Results |
Thalidomide and Temozolomide in Relapsed or Progressive CNS Disease or Neuroblastoma |
- Central Nervous System Tumor, Pediatric
- Neuroblastoma
|
- Drug: temozolomide
- Drug: thalidomide
|
Interventional
|
Phase 2 |
- Dana-Farber Cancer Institute
- National Cancer Institute (NCI)
- Boston Children’s Hospital
- (and 2 more...)
|
Other / NIH / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Therapy Completion Rate
- Overall Response
- Overall Survival
|
15 |
All |
up to 21 Years (Child, Adult) |
NCT00098865 |
01-279 DFCI
P30CA006516
CDR0000396780 |
|
September 2002 |
June 2010 |
June 2010 |
December 9, 2004 |
October 7, 2014 |
September 25, 2014 |
- Dana Farber Cancer Institute
Boston, Massachusetts, United States
|
|
| 47 |
NCT00442130 |
Active, not recruiting |
Reduced Intensity Stem Cell Transplantation for Chronic Lymphocytic Leukemia Followed by Vaccination |
- Chronic Lymphocytic Leukemia
|
- Biological: GM-K562 vaccine
- Procedure: stem cell transplantation
|
Interventional
|
Phase 1 |
- Dana-Farber Cancer Institute
- Brigham and Women's Hospital
- Dana-Farber Cancer Institute
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To assess the safety and toxicity of vaccination with lethally irradiated autologous CLL cells admixed with GM-562 cells following reduced intensity allogeneic stem cell transplant for CLL patients with advanced disease.
- To characterize the biologic activity in response to vaccination with lethally irradiated autologous CLL cells admixed with GM-562 cells, following reduced intensity allogeneic stem cell transplant
- to estimate duration of disease response, disease free and overall survival.
|
40 |
All |
18 Years and older (Adult, Older Adult) |
NCT00442130 |
06-196 |
|
February 2007 |
February 2014 |
July 2021 |
March 1, 2007 |
July 27, 2017 |
|
- Dana-Farber Cancer Institute
Boston, Massachusetts, United States
|
|
| 48 |
NCT01853748 |
Active, not recruiting |
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial) |
|
- Drug: Trastuzumab
- Drug: Paclitaxel
- Drug: Trastuzumab emtansine
|
Interventional
|
Phase 2 |
- Dana-Farber Cancer Institute
- Dana-Farber Cancer Institute
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Disease Free Survival in Patients Treated with T-DM1
- Disease Free Survival in Patient Groups Defined by Tumor Size
- Percentage of participants with Grade 3-4 Cardiac Dysfunction
- (and 3 more...)
|
512 |
All |
18 Years and older (Adult, Older Adult) |
NCT01853748 |
13-048 |
|
May 2013 |
December 2018 |
December 2021 |
May 15, 2013 |
February 1, 2018 |
|
- University of Alabama Birmingham
Birmingham, Alabama, United States - University of California San Francisco
San Francisco, California, United States - Hartford Hospital
Hartford, Connecticut, United States - (and 80 more...)
|
|
| 49 |
NCT01323920 |
Completed
Has Results |
Bortezomib-based GVHD Prophylaxis After Allogeneic Transplant for Patients Without Matched Related Donors |
- Leukemia
- Lymphoma
- Myelodysplastic Syndrome
|
- Drug: Bortezomib
- Drug: Tacrolimus
- Drug: Methotrexate
|
Interventional
|
Phase 2 |
- Dana-Farber Cancer Institute
- Dana-Farber Cancer Institute
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The Cumulative Incidence of Grade II-IV Acute GVHD up to Day 100 After Stem Cell Infusion
- The Percentage Donor Engraftment up to Day 30 Post Stem Cell Infusion
- The Non-relapse Mortality, Progression-free and Overall Survival up to 1 Year After Stem Cell Infusion
- The Cumulative Incidence of Chronic GVHD Requiring Systemic Immune Suppression up to 1 Year After Stem Cell Infusion
|
35 |
All |
18 Years to 60 Years (Adult) |
NCT01323920 |
11-007 |
|
May 2011 |
February 2013 |
November 2013 |
March 28, 2011 |
May 30, 2017 |
March 31, 2014 |
- Dana-Farber Cancer Institute
Boston, Massachusetts, United States
|
|
| 50 |
NCT00126191 |
Terminated
Has Results |
Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma |
- Burkitt Lymphoma
- Non-Hodgkins Lymphoma
- Atypical Burkitt Lymphoma
|
- Drug: Rituximab
- Drug: Cyclophosphamide
- Drug: Doxorubicin
- (and 7 more...)
|
Interventional
|
Phase 2 |
- Dana-Farber Cancer Institute
- Beth Israel Deaconess Medical Center
- Brigham and Women's Hospital
- Dana-Farber Cancer Institute
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Response Rates (CR and PR) in Adults With Burkitt/Atypical Burkitt
- Disease Free Survival
|
10 |
All |
18 Years and older (Adult, Older Adult) |
NCT00126191 |
04-336 |
|
July 2005 |
December 2009 |
June 2011 |
August 3, 2005 |
May 23, 2013 |
May 23, 2013 |
- Dana-Farber Cancer Institute
Boston, Massachusetts, United States - Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
|
|
Create an RSS feed from your search for:
Download the search results for: